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Cellular signaling controls an organism’s molecular milieu in two ways—by facilitating internal
growth and development, as well as responding to external stimuli, which includes response
to environmental stress and drug effects. Signaling networks control the information flow at
molecular level in a robust manner despite some inherent noise, tightly controlling the molecular
determinants of homeostatic balance. Several drug candidates are under trial for neurodegenerative
disorders for which molecular mechanism is not known in detail. Most drugs act on more
targets (including off-targets) than previously thought. Studying the mechanisms of drug action
is thus important not only for understanding biology, but also for design of more potent
therapeutic molecules. If the molecular underpinnings are adequately understood, those can be
easily tinkered with without causing toxicity or adverse effects. Exploration of mechanisms of drug
action by studying drug-induced signaling perturbations using quantitative proteomics is gaining
momentum (Sacco et al., 2016).
Yu and coworkers recently studied the phosphoproteomic changes in neuro-2a cells challenged
by cytotoxicity from Aβ25−35 peptide and the reversal of the changes by drug candidate- GFKP-
19, a 2-pyrrolidone derivative compound (Yu et al., 2016). Using SILAC labels, three different
treatment conditions were studied in neuro-2a cells- light (DMSO control), medium (cells with
Aβ25−35) and heavy (Aβ25−35 + GFKP-19) on Q-Exactive (QE) and Q-Exactive HF (HF) mass
spectrometers. Specific phosphorylation changes were captured with ∼25,000 phosphorylation
sites of which ∼18,000 have high localization probability. The important regulatory perturbations
in phosphoproteome studies at 4 and 24-h in each condition were captured and as expected, the
authors found that the 4-h time period shows more regulation of the phosphoproteome than 24-h,
since the signaling changes in phosphoproteins will be driving the information flow in early time
period. Regulated phosphosites between control vs. Aβ-treatment and drug vs. Aβ were observed
to control cytoskeletal protein functions. Authors also found Tau phosphorylations, which are
known causative agent of aggregation in AD. Proline directed kinase (PDK) motifs were found in
motif analysis along with basophilic motifs in both Aβ treatment and the drug rescue conditions.
Oxidative damage due to aggregation is caused by superoxide radicals binding to NO which
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can be formed by nitric oxide synthases (NOS1, NOS2, or
NOS3). Aβ induces phosphorylation of NOS1 at S847 which is
reversed by GFKP-19 bringing down oxidative damage. Another
site S479 of ASPP2 increased with Aβ treatment was rescued
by the drug but the functional aspect of this site is unknown.
Six sites in Tau protein were upregulated out of 20, which
had known counterparts in humans and the drug reversed
the effect in all 6 sites. From the interaction network, authors
postulated that phosphorylation of MARK2 and MAPK14 may
be involved in AD based on several phosphosites although
many previously known sites were not observed. For more
depth in understanding, profiling of these molecular changes
in phosphoproteome at a finely-resolved temporal level will
be interesting, as literature has shown phosphoproteome level
regulation starts much earlier than studied here. This may
require a multiplexed quantitative proteomics technique like
hyperplexing combining SILAC and iTRAQ (Kumar et al., 2016),
or the label free SWATH. While SWATH is experimentally
more challenging, hyperplexing is experimentally much easier,
even though costlier in comparison. For validation and
quantitation of PTM sites in a targeted manner, selected reaction
monitoring (SRM) can be employed on a triple quadrupole mass
spectrometer (Lange et al., 2008).
Role of Tau protein hyperphosphorylation is already well
known in AD and is not a surprise that the authors chose
to study Tau phosphosites in detail. Yet, it was interesting
to find out newer phosphosites regulated in drug mediated
protective mechanisms. It is also well accepted that all sites
of phosphorylation may not be functional and transient
non-specific phosphorylation sites may be captured in the
experiments; a detailed site-mutational study may be warranted
to check the functional significance of the mapped sites (Beltrao
et al., 2012). While the study of phosphoproteome is deeply
profiled and quantified, AD is a disease caused by dysfunction of
microtubules assembly and function. O-GlcNAcylation is greatly
reduced in AD leading to increased Tau hyper-phosphorylation.
Tubulin assembly and maintenance is also arbitrated by
several other PTMs and perhaps their dynamic crosstalk.
Several modifications like detyrosination, acetylation, and
polyglutamylation are known to govern assembly maintenance
and function of α-tubulin and microtubules. Several tubulin
modifications have a compensatory effect against microtubule
destabilization in susceptible neurons in AD (Zhang et al.,
2015). It will be interesting to see follow-up studies on
coordinated action of phosphoproteome with other PTMs
like acetylation and ubiquitination using serial enrichment
(Mertins et al., 2013).
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